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ABSTRACT 
ANUBHA SINGH: Tuberculosis Trends and Recommendations: Disproportionate decline in 
United States Populations and Recommendations to eliminate these disparities 
(Under the direction of Lori Evarts and Karl Drlica) 
 
Many people believe that tuberculosis (TB), like smallpox, is a disease of the past, and they are 
surprised to learn that tuberculosis still exists in the United States.  On a global basis, TB 
continues to be the leading cause of death for adults from an infectious disease [12]. Despite a 
steady decrease in the annual rate of TB cases since 1992, TB is a major public health threat in 
the United States, largely due to immigration from high-burden countries [4].  As reported by the 
Center for Disease Control and Prevention (CDC), in 2008 a total of 12,898 incident TB cases 
were reported; the TB case rate declined 3.8% from the 2007 case rate to 4.2 cases per 100,000 
population, the lowest rate recorded since reporting began in 1953 [10]. However, since 2000, 
the U.S. rate of decline has slowed considerably, and we are still far from meeting the goal of TB 
elimination. Although TB rates have fallen dramatically in the U.S.-born population, rates in the 
foreign-born population have declined much more slowly, and they now account for 59% of total 
incident cases of TB in the United States [10].  Further, Multi-drug Resistant Tuberculosis (MDR 
TB) continues to be a public health concern and has been shown to also disproportionately affect 
foreign-born persons in the United States. Increased travel and immigration of persons from 
countries with a high tuberculosis burden are certain to bring new challenges to public health. 
Future efforts to curtail the incidence of TB will require vigilant public health efforts that 
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include: education of patients and health care personnel; identification of routes and mechanisms 
of transmission; and assuring adequate treatment among infected individuals, and adequate 
prophylactic regimens among those with latent infection. An understanding of TB epidemiology 
coupled with increasing awareness about TB disparities will contribute to more effective 
targeting of prevention and control efforts.  
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Introduction 
Tuberculosis (TB) is one of the world’s deadliest diseases: one-third of the world’s 
population is infected with tuberculosis, in most cases without obvious symptoms [28]. Each 
year about 9 million people become ill with tuberculosis, and almost 2 million TB-related deaths 
occur worldwide [28].  Starting in the 1940s, scientists discovered the first of several drugs now 
used to treat TB. As a result, the number of TB cases slowly began to decrease.  Rates decreased 
steadily until the mid 1980s when they suddenly reversed. A number of factors were implicated 
in this temporary resurgence of TB, most notably immigration from countries having a high 
prevalence of disease, infection with the human immunodeficiency Virus (HIV), deterioration of 
social conditions, particularly in large urban areas containing large populations of homeless 
persons and incarcerated individuals, dwindling support for tuberculosis clinics and services, and 
emergence of MDR TB [4]. By 1992, the total number of cases of tuberculosis in the United 
States had risen to their highest in decades.  In some large cities, such as New York City, the 
rates of tuberculosis equaled rates seen in much poorer regions of the world [4].  However, with 
increased funding, intense control efforts, and attention to the TB problem, the number of cases 
began to decline. 
Since the 1992 TB resurgence peak in the United States, the number of TB cases reported 
annually has decreased by 50% (Figure 1) [29].  However, the trend of the declining annual case 
rate has slowed, from an annual average decline of 7.3% for 1993 through 2000 to an annual 
average decline of 3.8% for 2000 through 2008 [10]. In 2008, a total of 12,898 TB cases were 
reported; the TB rate declined 3.8% from the 2007 rate to 4.2 cases per 100,000 population, the 
lowest rate recorded since reporting began in 1953 [10].  Although rates have fallen dramatically 
in the U.S.-born population, rates in the foreign-born U.S. population have declined much more 
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slowly and now account for a much higher percentage of total cases (Figure 2) [29].  As 
demonstrated in Figure 3, foreign-born persons have accounted for the majority of TB cases in 
the United States every year since 2001. In 2008, the TB rate in foreign-born persons in the 
United States (20.3 cases per 100,000 persons) was ten times greater than that of U.S.-born 
persons (2.0 cases per 100,000 persons) [10].  Also of note, 58.8% of all TB cases in the United 
States occurred in foreign-born persons in 2008 [10]. This difference reflects the high rates of TB 
in countries of origin for U.S. immigrants, the continuous influx of persons with high prevalence 
of latent infection, and reactivation of latent tuberculosis infection [5].  Several factors likely 
contribute to the burden of TB in minority populations residing in the United States: (a) among 
people from countries where TB is common, TB disease may result from an infection acquired in 
the country of origin, (b) among racial and ethnic minorities of native born persons, unequal 
distribution of TB risk factors, particularly HIV infection, can increase the chance of developing 
the disease. However, the percentage of TB cases with a known HIV-positive diagnosis has 
continued to decline since the peak of the TB resurgence in 1992 [4].  
 Effective control of tuberculosis requires an understanding of its changing epidemiology, 
which in turn is required for identifying populations that are high-incidence and at risk for 
developing active disease. Identifying such populations will help the public and private sectors 
allocate necessary resources to combat the disease. This paper identifies current trends of 
tuberculosis in the United States and makes recommendations that will help reduce the number 
of incident cases among minority populations and thus close the gap between the different sub-
populations and hopefully bring us closer to the goal of TB elimination in the United States. 
 
8 
 
Sources of data 
Health departments in the 50 states and the District of Columbia (DC) electronically 
report to CDC verified TB cases that meet the CDC/Council of State and Territorial 
Epidemiologists case definition.  Reports include the patient's race, ethnicity (i.e., Hispanic or 
non-Hispanic), treatment information, and, whenever available, drug-susceptibility test results. 
CDC calculates national and state TB rates overall and by racial/ethnic group using current U.S. 
census population estimates. U.S. census annual estimates were used to calculate the national TB 
rate and the percentage change from 2007 to 2008. Population denominators used to calculate 
TB rates and percentage changes over time according to national origin (U.S.-born versus 
foreign-born persons) were obtained from the U.S. Census Current Population Survey [25]. A 
U.S.-born person was defined as someone born in the United States or associated jurisdictions or 
someone born in a foreign country but having at least one U.S.-born parent. Persons not meeting 
this definition were classified as foreign-born. For 2008, this Survey noted that patients with 
unknown origin of birth represented 0.6% (74 of 12,898) of total cases [25]. Persons identified as 
white, African-American, Asian, American Indian/Alaska Native, native Hawaiian or other 
Pacific Islander, or of multiple races were all classified as non-Hispanic. Persons identified as 
Hispanic might be of any race.  
As reported by the Center for Disease Control and Prevention (CDC) in their Morbidity 
and Mortality Weekly Report in 2009 [10], the numbers and rates of TB included in this paper 
for the year 2008 are provisional and subject to marginal change. This applies to TB case count 
and HIV testing results, both of which were incomplete at the writing of this paper. Population 
denominator data were drawn from multiple U.S. Census sources and are subject to periodic 
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adjustment. CDC’s annual TB surveillance summary, due to be published this fall, will provide 
updated data.   
TB in U.S.-born persons vs. foreign–born persons 
 Among U.S.-born persons, the number of TB cases continued to decline in 2008 (Figure 
2) [29]. In 2008, the TB rate among U.S.-born persons was 2.0 cases per 100, 000 population, 
representing a 4.7% decline since 2007 and a 72.6% decline since 1993 [10].  African-American, 
non-Hispanic persons continue to have a disproportionate share of TB in the United States.  The 
proportion of TB in African-American, non-Hispanic persons is even greater if only U.S.-born 
persons reported with TB are examined. U.S.-born persons represented 42% of all TB cases 
reported in the United States in 2007 [10]. And among these U.S.-born persons reported with 
TB, 45% were African-American, non-Hispanic persons (Figure 4) [29]. TB rates for U.S.-born 
African-Americans were seven times higher than the rates for U.S.-born whites [10, Table].  
The TB rate among foreign-born persons in 2008 was 20.2 per 100,000 population, which 
represents a 2.6% decline since 2007 and a 40.6% decline since 1993 [10].  Figure 5 shows 
trends in TB cases in foreign-born persons in the United States from 1988 through 2008. The 
number of TB cases in foreign-born persons has increased from nearly 5,000 in 1988 to 7,000–
8,000 per year since 1991 [29]. In 2008, more TB cases were reported among Hispanics than any 
other racial/ethnic group, followed by Asians and African-Americans [10, Table]. Asians had the 
highest TB case rate among all racial/ethnic groups [10, Table].  In the same year, four countries 
accounted for approximately half of foreign-born TB cases: Mexico, Philippines, India and 
Vietnam [10]. 2008 witnessed a decline in TB rates for all racial/ethnic minority groups; the 
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greatest annual decline from 2007-2008 was among African-Americans (-7.0%), followed by 
Hispanics (-5.1%) and Asians (-4.6%) [10, Table]. 
The findings of a study conducted by the CDC in seven southeastern states showed that 
non-Hispanic African-Americans were more likely than non-Hispanic whites to report certain 
risk factors (drug use, excessive alcohol use, incarceration, and infection with HIV) that are often 
associated with being socioeconomically disadvantaged or immunocompromised [6]. 
Differences in socioeconomic status have been identified as key predictors of TB rates. As of 
2002, the South had the highest percentage of households with incomes below the federal 
poverty level (13.8%) of any region in the United States; this might account for the higher TB 
rate among non-Hispanic whites in the seven southeastern states [6]. In another study, TB in 
African-Americans was associated with younger age, inner city residence, and HIV 
seropositivity [17].   
Latent Tuberculosis Infection (LTBI) 
 There are several possible outcomes when a person encounters M. tuberculosis bacilli. 
First, the bacillus can be immediately destroyed by the host’s innate immune response. For 
several weeks after initial infection, the pathogen battles the innate immune response, leading to 
induction of an acquired immune response. In most individuals that do not immediately eradicate 
the pathogen, the acquired immune response controls bacterial growth, which prevents 
progression to clinical disease. However, 5-10 % of individuals develop active disease within 1-3 
years [21]. Unlike the risk of getting infected with the bacterium, the risk of developing disease 
depends on a number of endogenous factors such as a person’s innate susceptibility to disease 
and the level of function of cellular immunity. The net effect is that the majority of persons 
infected with M. tuberculosis (90-95%) acquire a clinically latent infection [21]; that is, they are 
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infected and become purified-protein-derivative positive (PPD-positive) by skin test. However, 
they do not present with clinical symptoms; moreover, they are not considered to be contagious. 
 Dormant bacilli may persist for many years inside structures called granulomas before 
reactivating and causing tuberculosis. When the immune system fails, the infection reactivates to 
cause active disease. The continued high burden of global tuberculosis and immigration to the 
United States in persons from high-burden countries means that there will be a persistent 
reservoir of infection in persons in the community that will be a source of reactivation disease in 
the future.  Estimated national prevalence of latent tuberculosis infection (LTBI) in the United 
States decreased from 14.3% in the early 1970s to 5.7% in 1999-2000 [2]. A survey by Bennett 
et al., 2008, concluded that 4.2% of the civilian, non-institutionalized U.S. population or 
11,213,000 individuals had LTBI in 1999-2000 [2]. Foreign-born survey participants had a 
significantly higher LTBI prevalence (18.7%) than participants born in the United States (1.8%) 
[2]. In Bennett et al.’s multivariate analysis, birthplace, race/ethnicity and household contact with 
a case of active tuberculosis were identified as independent risk factors for tuberculosis infection.  
Many foreign-born persons with LTBI never receive a skin test or any other type of 
evaluation such as a screening questionnaire to be considered as candidates for treatment of 
LTBI.  Studies of TB genotypes in the United States suggest that TB among foreign-born 
persons is typically due to reactivation of LTBI, for which infection was likely acquired before 
U.S. arrival [5]. Current TB strategies in the United States focus on interrupting recent 
transmission of disease, and thus it is understandable why current TB control strategies have 
limited success in a large subset of foreign-born populations that enter the United States with 
high rates of LTBI [5].    
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TB in prison populations 
M. tuberculosis infection is highly prevalent among prison populations worldwide, 
affecting 12-60% of inmates in surveyed systems [15]. United States correctional facilities have 
been implicated in tuberculosis outbreaks where transmission of M. tuberculosis has been 
associated with crowded living conditions and frequent relocation of inmates. A study by 
Saunders et al. estimated a 31% prevalence of M. tuberculosis infection among foreign-born 
inmates in the federal prison system, which is significantly higher than the 5% prevalence seen in 
U.S.-born prison inmates [15].  It is remarkably similar to the 32% prevalence of M. tuberculosis 
infection seen in the global population as estimated by the World Health Organization (WHO) 
[15]. The high prevalence of TB disease among foreign-born inmates entering the federal prison 
system presents a strategic opportunity to provide preventive therapy to a high risk population 
and to identify contagious cases that might elude traditional public health efforts.    
Multidrug-resistant tuberculosis (MDR TB)  
Multi-drug resistance (defined as resistance to at least two agents, generally isoniazid and 
rifampin) has been a source of great concern, especially in countries such as Russia and parts of 
the former Soviet Union, China, Korea, Brazil and South Africa [4]. One of the factors that fuels 
the spread of this resistance is that high drug prices create an opportunity to profit from illicit 
distribution of diluted medicines; ineffective doses select for drug-resistant strains. Another 
factor is failure to employ effective combination chemotherapy, particularly in cases where the 
two main drugs, isoniazid and rifampin, are prescribed, but the infecting strain is already 
resistant to one of them. This promotes selection for resistance to the other, creating MDR TB. 
This situation is difficult to avoid, since drug susceptibility testing (DST) is rarely utilized [18].  
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 A total of 125 cases of MDR TB were reported in the United States in 2007, the most 
recent year for which complete drug-susceptibility data are available [10]. Among culture-
positive cases with susceptibility testing performed, the percentage of TB cases that were MDR 
TB for 2007 (1.2%) was the same as the percentage for 2006 [10]. The percentage of MDR TB 
cases in persons with no previous history of TB that was reported in the United States has 
remained stable at approximately 1.0% since 1997 [10]. In 2007, the percentage of MDR TB 
cases among persons with a previous history of TB was 3.6% [10].  MDR TB continued to 
disproportionately affect foreign-born persons who accounted for 81.6% of MDR TB cases [10]. 
Foreign-born persons had higher percentages of MDR TB, both among persons with (5.2%) and 
without (1.5%) a previous history of TB [10]. These statistics indicate that MDR strains in 
foreign-born persons are acquired prior to entering the U.S., and they reflect inadequate 
tuberculosis control in those countries. While just 4.4% of U.S.-born persons with TB had 
isolates resistant to isoniazid, resistance was found in 11% of the isolates from recent entrants 
and in 10% of non-recent entrants [5]. This suggests that isoniazid treatment of LTBI in such 
individuals may be unsuccessful in a significant proportion of people who have emigrated from 
high incidence countries.  
Extensively Drug-Resistant Tuberculosis (XDR TB) 
With the growing numbers of MDR-TB worldwide, use of second-line TB drugs has 
increased without a concomitant strengthening of TB control programs to provide them in a safe 
and effective manner. As a result, TB cases with an ever expanding spectrum of drug resistance 
have emerged [18].  In 2006, the CDC, WHO, and the International Union Against Tuberculosis 
and Lung Disease (IUATLD) reported the results of a survey regarding drug-resistant TB 
conducted by 25 reference laboratories comprising the Global Supranational Reference 
14 
 
Laboratory Network, the National TB surveillance system in the United States (1993-2004), the 
national reference laboratory of South Korea (2004), and the national MDR TB patient registry 
in Latvia (2000-2002).  The findings indicated that 20% of M. tuberculosis isolates were MDR 
and 2% were also resistant to multiple second-line drugs [7]. This highly resistant form of TB 
was identified as a new TB disease category, termed extensively-drug resistant TB (XDR TB), 
and it was determined that XDR TB had emerged in all regions of the world [7,9]. 
XDR TB is defined as MDR TB that is also resistant to the most effective second-line 
therapeutic drugs used commonly to treat MDR TB: fluoroquinolones and at least one of three 
injectable second-line drugs used to treat TB (amikacin, kanamycin, or caperomycin) [7,9]. In 
the United States, defining the scope of XDR-TB and describing its epidemiology is important 
for healthcare professionals, public health programs, and policy makers. In the United States, the 
cost of hospitalization for one XDR TB patient is estimated to average $483,000, approximately 
twice the cost for MDR TB patients [9]. A major outbreak of XDR TB in the United States 
would constitute a substantial drain on public health resources. Moreover, XDR TB is of 
considerable concern in persons who are infected with HIV or who have other 
immunocompromising conditions. 
A study carried out by Shah et al., 2008, provides the first comprehensive assessment of 
the burden of XDR-TB in the United States and represents fifteen years of surveillance data from 
the beginning of TB drug resistance surveillance in 1993.  The annual number of XDR TB cases 
has decreased from eighteen in 1993 to two in 1997 with an average of 3.5 cases per year over 
the past decade [18]. Of the 83 cases of XDR TB in the U.S. from 1993 to 2007, the majority 
were seen in those 25-44 years of age (58%), male (64%), U.S.-born (54%), and unemployed 
(53%) [18]. Thirty-three (40%) of the cases were Hispanic [18]. Sociodemographic 
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characteristics did not differ between the XDR TB and the MDR TB cases. However, compared 
with the drug-susceptible cases, XDR TB cases were significantly less likely to be in the older 
age group.  XDR TB cases were more likely to be in the Hispanic population, and to be found in 
correctional facility residents. The study concluded that XDR TB cases had poorer treatment 
outcomes and higher mortality compared with MDR TB and drug-susceptible TB cases.  
Specifically, mortality rates were twice as high as with MDR TB cases, and more than 6 times 
greater than among drug-susceptible cases [18]. Shah et al. identified suboptimal treatment 
supervision by TB programs as one of the factors that contributed to poor outcomes.   
TB/HIV 
The HIV epidemic was a major factor in the resurgence of tuberculosis in the late 1980s 
and early 1990s [3]. Epidemiologic studies have indicated that HIV infection is the strongest 
predisposing factor for TB developing in persons with latent tuberculosis infection [16]. TB is 
the leading cause of death among persons who are HIV positive. HIV and TB form a lethal 
combination, each speeding the other’s progress.  As of 2005, CDC estimated that 9% of all TB 
cases and nearly 16% of TB cases among persons aged 25 to 44 were occurring in HIV-infected 
persons [8]. After TB exposure and infection, HIV-infected persons who do not receive 
appropriate treatment progress to TB disease over 5 years at a rate 10 times greater than that for 
persons not infected with HIV [8]. 
Albalak et al., 2007, reported trends in tuberculosis/HIV co-morbidity in the United 
States between 1993-2004 [1]. The study showed that the number of TB/HIV cases and TB/HIV 
co-morbidity rates remained stable among foreign-born persons in the United States (average, 
6.6%) from 1993-2004 and that the rate steadily decreased from 18% in 1993 to 11% in 2004 
among U.S.-born whites [1]. Thus, U.S.-born persons accounted for the entire decline in TB/HIV 
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cases. From 1993-2004, the number of TB/HIV cases declined by 84%, 63% and 66% for non-
Hispanic whites, Hispanics, and non-Hispanic African-Americans, respectively [1]. The authors 
concluded that the decrease may have been the result of a) more intense TB and HIV control 
efforts, such as interrupting TB transmission by isolating infected patients, b) decreasing 
transmission of TB in congregate settings, c) encouraging HIV testing, d) improved Highly 
Active Antiretroval Therapy (HAART), and e) expanding testing and treatment of LTBI among 
HIV-infected persons [1]. The introduction of HAART in 1996 likely contributed to the 
accelerated decline in TB/HIV co-morbidity that was seen in the United States during the 1996-
1999 reporting period. The TB/HIV co-morbidity rates were substantially higher in non-Hispanic 
African-Americans than in the other racial/ethnic groups for all years [1]. Although non-
Hispanic African-Americans contributed more than 50% of the decline in TB/HIV cases and 
experienced the greatest decline in the absolute number of TB/HIV cases compared with other 
racial/ethnic groups, the TB/HIV co-morbidity rate in this group remained more than double that 
of Hispanics and more than 4 times that of non-Hispanic whites [1]. Thus, continued progress in 
reducing TB/HIV co-morbidity will depend on sustaining these successes by increasing access to 
HIV diagnosis and care and reducing HIV transmission in high-burden and high-risk 
populations. Expanding HIV testing in high-risk groups, followed by TB screening, would help 
identify candidates for HAART and LTBI treatment and thus lead to an accelerated decline in 
TB/HIV in all racial/ethnic groups.  
Reasons for the observed disparity 
Reasons for disparity are multifactorial. In communities with high concentrations of 
foreign-born persons, excessive transmission of tuberculosis occurs because of delayed access to 
medical care resulting from any one of several factors including language barriers, fear of loss of 
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employment and income, fear over immigration status, and lack of health insurance [4].  It is also 
possible that the mode of tuberculosis development among foreign-born persons is different and 
that in fact there has been very little transmission in immigrant communities. Rather, cases have 
arisen mainly through reactivation of latent infection acquired before moving to the United 
States. A molecular epidemiology study by Geng and colleagues provided definitive evidence 
that most of the cases of tuberculosis among non-U.S. born persons result from reactivation of 
latent infection rather than increased transmission in their communities [13]. This theory was 
also supported by Burzynski and Schluyer who found that Restriction Fragment Length 
Polymorphism (RFLP) patterns from isolates obtained from non-U.S.-born persons were mostly 
unique, indicating that there was little transmission occurring in that population segment [4].  
A study conducted in seven Southeastern states concluded that non-Hispanic African-
Americans were more likely to report certain risk factors (such as drug use, excessive alcohol 
use, incarceration, infection with HIV) often associated with being socio-economically 
disadvantaged or immunocompromised, compared to non-Hispanic whites [6].  Serpa et al., 
2009, concluded that younger age, fewer years of education, use of public transportation, and 
inner city residence were independently associated with African-American race among TB 
patients in Houston, Texas [17].  These associations support the concept that TB remains 
predominantly a disease of disadvantaged and marginalized persons.   
Recommendations for reducing observed disparities in TB rates 
Although rates of TB in both African-Americans and whites have declined substantially 
over the past decade in the United States, huge disparities remain. We must better target our 
efforts to prevent and control TB in the African-American population. Differences in 
socioeconomic status have been identified as key predictors of TB rates and many studies have 
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shown that TB remains predominantly a disease of disadvantaged and marginalized persons.  
CDC’s TB Epidemiologic Studies Consortium is making efforts in this regard and is currently 
conducting studies to understand how to reduce TB in African-Americans.  The Consortium’s 
work includes a study to identify barriers to treatment adherence for latent TB infection and TB 
disease, and a study examining the determinants of early diagnosis, prevention, and treatment of 
TB [10].  Directly Observed Therapy (DOT) is recognized in the United States as a critical 
component of successful TB treatment. Once African-Americans enter a TB program, a high 
percentage are known to receive DOT [10]. The percentage of non-Hispanic African-Americans 
receiving DOT is consistent with their low rate of infection with MDR TB [10]. These 
performance measures indicate successful management of DOT programs in the non-Hispanic 
African-American population [10]. However, it is not cost effective to screen and treat all 
African-Americans. Targeted testing and treatment of the high incidence populations is thus 
recommended.   
Controlling LTBI and TB disease in the foreign-born population in the United States is a 
challenge that requires an understanding of TB epidemiology and increasing awareness about TB 
disparities. Cases of TB among foreign-born persons can be prevented by more widespread 
testing and treatment of LTBI in those communities. However, this is easier said than done. 
Many persons born outside the U.S. do not accept the diagnosis of LTBI because they hold the 
belief that prior BCG (Bacillus of Calmette and Guerin) vaccination causes false-positive skin 
test results and are unwilling to accept a recommendation for therapy based on a skin test [4].   
The QuantiFERON-TB Gold test (QFT-G), a whole blood test approved by the Food and Drug 
Administration (FDA) in 2005, is one option for implementation as part of the screening 
program and could be used to correctly diagnose LTBI.  One of the challenges of TB control 
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through targeted screening and LTBI treatment is to design screening programs that are feasible 
and cost-effective and at the same time conducted in a manner that does not promote racial 
discrimination. However, since it is not feasible to screen and treat everyone, one way is to 
identify which populations of foreign-born persons in the U.S. would benefit most from LTBI 
testing and treatment.  This could be achieved through a survey of foreign-born TB patients in 
the United States to determine opportunities for improving prevention and control interventions. 
One successful example comes from a study conducted by Sipan et al., to detect the rate of LTBI 
in a sample of young people in San Diego County [19]. The study concluded that Latino 
adolescents and foreign-born adolescents were high-risk populations for TB in San Diego 
County and should be targeted in future screening efforts [19]. Consequently, implementing 
targeted screening programs in high-risk individuals through schools has its advantages. It is 
easy to find adolescents in large numbers, to identify those who have demographic 
characteristics predictive of LTBI risk, and to provide an organizational base to conduct 
screening and follow-up on treatment recommendations. Another targeted screening program 
would include the identification of populations that need enhanced overseas screening prior to 
U.S. entry. Enhanced overseas pre-immigration screening of immigrants and refugees for TB 
disease would include obtaining a TB culture in addition to current screening practices. 
Currently, chest radiography is performed overseas for all U.S.-bound immigrants and refugees 
older than 15 years of age, and a sputum-smear microscopic analysis for acid-fast bacilli is 
performed for individuals with an abnormal chest radiograph or symptoms of TB disease. 
Unfortunately, individuals entering the United States such as illegal immigrants, students, 
workers, and visitors are not subjected to the same screening.  These individuals comprise 30% 
of all foreign-born persons in the U.S.  As a start, enhanced overseas screening prior to U.S. 
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entry should be expanded to include those wishing to enter the United States on a student or a 
visitor’s visa.  Moreover, LTBI treatment and testing among recent entrants from the known 
highest-risk countries should be a high priority. Although a 9-month regimen of isoniazid is the 
preferred treatment for LTBI, a 6-month regimen also provides substantial protection and has 
been shown to be superior to placebo for both HIV-infected and HIV-uninfected persons [11].  
Another successful example of targeted efforts is the CDC’s African Refugee Women’s Health 
Improvement Project [20, 24].  This project was initiated with the aim to address disparities in 
tuberculosis in foreign-born women.  Further, the project was designed to increase the capacity 
of the public health system in Massachusetts to respond to the needs related to tuberculosis as 
well as to increase understanding of strategies to improve health outcomes among African 
refugee women who have settled in the area [20, 24].  This is a program that is continuing and 
should be emulated in other parts of the country to identify TB control and prevention strategies 
in specific subpopulations. 
For reducing the incidence and transmission of tuberculosis among the incarcerated 
population, prisons need to have a universal screening system for inmates such as a skin test 
followed- up with a chest radiograph for those with a positive skin test. HIV testing should be 
strongly encouraged among those diagnosed with TB or LTBI. Additionally, when inmates are 
known to be HIV-positive, aggressive TB screening should be implemented. Once an inmate has 
started TB treatment, support systems should be in place for ensuring continuity of care after 
release from the prison, as inmates are often released before treatment completion and are lost to 
follow-up.  That leads to development of resistance. A strong collaboration with the local public 
health departments in the form of standard follow-up procedures once an inmate is released from 
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prison can help prisons ensure that such inmates would continue to receive treatment upon 
release. 
In 2008, those from Mexico accounted for the highest number of TB cases (1,742) among 
the foreign-born populations residing in the United States [10]. It is obvious that tuberculosis 
control in the United States will not be achieved without meaningful cooperation between the 
U.S. and Mexico. Mexico is considered a moderate TB-rate country, with a prevalence of 2.5 
times that of the U.S.[19].  This rate compounded with Mexico’s proximity to the U.S., and 
ongoing frequent mixing of U.S. and Mexican populations (especially along the 2000-mile U.S.–
Mexico border) increases the importance of effective TB screening and TB control, particularly 
among the border communities. Rapid and sensitive screening tests need to be developed which 
would take minutes instead of hours and could be administered at border crossings. Moreover, 
improved coordination of TB control activities through local public health departments is 
required between United States and Mexico to ensure completion of treatment among TB 
patients who cross the border.  
Preventing and controlling tuberculosis in foreign-born persons requires special 
resources.  For example, in Fairfax County, Virginia, public health workers employ 32 languages 
when talking with residents about tuberculosis [23]. Serving foreign-born patients also requires 
healthcare worker’s with cross-cultural training who can work effectively with patients and their 
families and with community-based organizations that address the medical and other needs of 
immigrants and refugees. Health-care workers should also be able to address issues around 
homelessness, substance abuse and a variety of lifestyles that will allow them to interact 
effectively with high risk groups. 
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We could make larger financial investments in domestic and global TB control. The past 
decade has seen a major influx of resources for TB research, mostly from the National Institutes 
of Health (NIH), The Bill and Melinda Gates Foundation, and the European Union. Nonetheless, 
resources remain insufficient to achieve global TB control. Available funding for global TB 
control reached $3.3 billion in 2008, up from less than $1 billion in 2002; however the gap 
between available and required resources is estimated to be around $1 billion [22]. The 
increasing expenditure required to treat and manage MDR TB and XDR TB cases is one 
contributing factor to this gap.  Both the public and private sectors need to invest in TB control. 
TB prevention and control capacity in the form of a trained public health workforce should be 
increased. Treating persons with LTBI can effectively reduce the risk of developing active 
disease by 90%. Without treatment, the 10 million to 15 million people with LTBI represent 
more than a million future cases of active TB-themselves, as well as those infected after 
developing active disease (estimated to be 10-15 new cases per year) [27].  
There is a need to educate U.S. healthcare providers about TB, diagnostic methods, 
prevention, and treatment to reduce the incidence of MDR and XDR TB. As a result of 
decreasing TB rates in the United States, U.S. healthcare providers have received little or no 
training diagnosing TB.  Consequently, these providers may miss the signs or symptoms of TB 
that could in turn lead to incorrect TB diagnosis and treatment, development of drug-resistance 
TB, and continued spread of TB in the community.   For example, concluding that an actual case 
of TB is instead pneumonia could lead to monotherapy with a fluoroquinolone that can lead to 
fluoroquinolone-resistant TB [14].  Further, tailored and targeted educational materials on MDR 
TB and XDR TB should be developed for:  the public; TB patients; policy makers; TB 
prevention advocacy organizations; and populations at high-risk for TB, on the basis of 
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demographic and clinical characteristics.  Advocacy is critical to increase public awareness and 
to educate policy makers on the magnitude of the problems that will result if resources to state 
and local TB control programs continue to decline. Research of associated behavioral and social 
factors should be conducted to identify ways to improve patient compliance and treatment 
completion, because poor patient adherence to therapy is one factor that can lead to the 
development of MDR TB and XDR TB.  
Conclusions   
 Closing the gap in TB rates between U.S.-born and foreign-born persons is critical for 
achieving the National TB Program Objectives [26] and Performance Targets for 2015 [26] and 
ultimately the goal of TB elimination in the United States. This can be achieved by stopping the 
influx of new TB cases from high-burden countries through expanded and more aggressive 
overseas pre-entry screening, and by providing prophylactic treatment to individuals diagnosed 
with LTBI and at a high risk for developing reactivation tuberculosis after entering the United 
States.  Success in the United States will depend on TB programs that provide services to 
foreign-born persons with latent TB infection and also on collaborative efforts to reduce the 
burden of TB disease globally.  This can only be achieved by 1) optimizing overseas screening 
of immigrants and refugees, 2) establishing a bilateral TB referral and case management system 
between the United States and Mexico to improve completion of treatment by TB patients who 
cross the U.S.-Mexico border, 3) identifying and treating persons from high-incidence countries 
who have LTBI, and 4) last but not the least strengthening ties with international organizations, 
such as the WHO, to help improve TB control in high-incidence countries. 
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Figure 1: Reported TB Cases, United States, 1982–2008. The resurgence of TB in the mid-
1980s was marked by several years of increasing case counts until its peak in 1992. Case counts 
began decreasing again in 1993, and 2008 marked the sixteenth year of decline in the total 
number of TB cases reported in the United States since the peak of the resurgence. From 1992 
until 2002, the total number of TB cases decreased 5%–7% annually. From 2002 to 2003, 
however, the total number of TB cases decreased by only 1.4%. In 2008, a total of 12,904 cases 
were reported from the 50 states and the District of Columbia. This represents a decline of 2.9% 
from 2007 and of approximately 50% from 1992. 
(http://www.cdc.gov/tb/statistics/surv/surv2008/default.htm) 
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Figure 2: TB Case Rates in U.S.-born vs. Foreign-born Persons, United States, 1993–2008. 
TB rates in foreign-born persons remain higher than those in the U.S.-born population. From 
1993 through 2008, the rates in U.S.-born persons decreased from 7.4 per 100,000 to 2.0, 
whereas the rates in foreign-born persons decreased from 34.0 per 100,000 to 20.3. The rates are 
presented on a logarithmic scale to better illustrate the trend in TB rates among the U.S.-born and 
foreign-born. The lines show a greater rate of decline among the U.S.-born compared with the 
foreign-born during this period. (http://www.cdc.gov/tb/statistics/surv/surv2008/default.htm) 
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Figure 3: Number of TB Cases in U.S.-born vs. Foreign-born Persons, United States, 1993–
2008. This graph plots the number of U.S.-born vs. foreign-born persons reported with TB each 
year, from 1993 through 2008. It illustrates the increase in the percentage of cases occurring in 
foreign-born persons during this period, from 29% in 1993 to 58% in 2008. Overall, the number 
of cases in foreign-born persons remained virtually level, with approximately 7,000–8,000 cases 
each year, whereas the number in U.S.-born persons decreased from more than 17,000 in 1993 to 
less than 5,300 in 2008. (http://www.cdc.gov/tb/statistics/surv/surv2008/default.htm) 
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Figure 4: Reported TB Cases by Origin and Race/Ethnicity, United States, 2007. Among 
U.S.-born persons with TB in 2007, 45% were non-Hispanic African-American or African-
American, 33% were non-Hispanic white, 16% were Hispanic or Latino, 3% were American 
Indian or Alaska Native, 2% were Asian, and 1% were Native Hawaiian or Other Pacific 
Islander.  
(http://www.cdc.gov/tb/statistics/surv/surv2008/default.htm) 
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Figure 5: TB cases in Foreign-born Persons, United States, 1988 – 2008.  The number of TB 
cases in foreign-born persons increased from nearly 5,000 in 1988 to 7,000–8,000 each year 
since 1991. The percentage of TB cases accounted for by foreign-born persons increased from 
22% in 1988 to 59% in 2008.  
(http://www.cdc.gov/tb/statistics/surv/surv2008/default.htm) 
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